AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 172 min read$CMND

Clearmind Medicine Briefs FDA On Patient Access At Psychedelic Hearing

Clearmind Medicine (CMND) presented at an FDA hearing on psychedelic drugs, discussing patient access. The company's Chief of Global Impact shared insights from its MEAI clinical trial at Yale and Johns Hopkins, suggesting non-hallucinogenic treatments could expand access. CMND's stock is up 21.72% to $0.97.

Original reporting
rttnews.com
Published Sep 17, 2026, 6:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 7:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$CMND
Bullish
medium confidence
Mentioned
$CMND
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CMNDBullishLow
01

Why it matters

The FDA hearing provides a platform for the company to influence future policy and may improve market perception.

02

Market read

Regulatory exposure could modestly affect CMND stock; broader sector may see increased attention.

03

What to watch

Potential delays in trial enrollment and FDA approval timeline.

Relevance 6/10Novelty 6/10Timing: post‑hearing Sep 14 2026

Background

Clearmind Medicine is a micro‑cap biotech developing non‑hallucinogenic psychedelic candidates.

Company-level read

Ticker impact

$CMNDBullishMedium confidence
Context

Clearmind Medicine testified at an FDA hearing on psychedelic drug access, providing fresh regulatory exposure.

Expected impact

Modest upside if FDA signals support for non‑hallucinogenic psychedelics.

Evidence & confidence

The hearing is an early step; no decision yet, but visibility may attract speculative buying.

Market effects

Sector

May raise interest in neuroplastogen biotech sector.

Regional

Limited to U.S. biotech investors.

Global

Low global impact; niche therapeutic area.

Counterpoint

What could challenge this read

Regulatory hearings rarely translate to price moves; risk of over‑optimism.

Key entities

  • Company
    Clearmind Medicine Inc.

    Developer of MEAI, a non‑hallucinogenic psychedelic candidate.

  • Regulator
    U.S. Food and Drug Administration

    Conducting hearing on psychedelic drug access.

Read at source← All news

Related articles

SEP 11
$CMNDMedAI 8/10

Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

finanznachrichten.de2 min
SEP 8
$CMNDMed

Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

rttnews.com2 min
SEP 4
$CMNDMed

Clearmind Tumbles on Buying into Charging Robotics

Clearmind Medicine (CMND) agreed to buy a 51% stake in Charging Robotics, a wireless EV charging solutions provider, for $2.5M. The company will also lend Charging Robotics $1.5M at 4% interest. Charging Robotics' tech offers up to 10 kW continuous charging for automated parking and autonomous vehicles.

baystreet.ca1 min
SEP 1
$CMNDMedAI 8/10

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine (CMND) has started Phase IIa of its trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled. The trial is evaluating safety, tolerability, and preliminary efficacy. The company reported positive data from earlier trial phases, supporting continued development. CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic.

sina.com.hk2 min
AUG 13
$CMNDMed

Clearmind Medicine Inc.: Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

Clearmind Medicine (Nasdaq: CMND) said its independent DSMB approved advancing its FDA-regulated Phase I/II trial of CMND-100 for alcohol use disorder from Part A to Parts B and C. Part A met the primary safety endpoint in healthy participants. Part B will test 80 mg and 160 mg in AUD patients; Part C will test 160 mg in healthy participants.

finanznachrichten.de4 min